Nvidia's NVentures Buys 833,325 Generate Biomedicines Shares in $13 Million AI Drug Bet
Updated
Updated · The Motley Fool · Jun 27
Nvidia's NVentures Buys 833,325 Generate Biomedicines Shares in $13 Million AI Drug Bet
3 articles · Updated · The Motley Fool · Jun 27
Summary
$13 million bought Nvidia's venture arm 833,325 shares of Generate Biomedicines, a roughly $2 billion biotech developing AI tools to model how drug candidates may perform against disease.
Generate's platform is already feeding a real pipeline: four drug candidates are in development, including GB-0895 for severe asthma, which has reached phase 3 testing.
The pitch is speed and efficiency in an industry where bringing one approved drug to market can take 10 to 15 years and about $2.6 billion, while only about 1 in 10 clinical-stage drugs win approval.
AI-discovered drugs are cited as roughly twice as likely to succeed in phase 1 trials, and the broader AI drug-development market is projected to reach $160 billion a year by 2035 from under $20 billion last year.
Can Generate's AI platform out-innovate tech giants like Alphabet to truly revolutionize drug discovery?
Will AI's promise of cheaper drug development lead to more affordable breakthrough medicines for patients?
As AI designs more drugs, how will regulators ensure patient safety without stifling life-saving innovation?
Nvidia’s Strategic Stake in Generate Biomedicines: How AI is Doubling Drug Discovery Success Rates
Overview
Nvidia's recent investment in Generate Biomedicines highlights its ambition to expand AI leadership into high-impact sectors like pharmaceuticals. By backing Generate's pioneering AI-powered platform, Nvidia aims to secure a stake in a company poised to disrupt the $1.8 trillion drug market. Generate, still in its clinical stage and not yet generating significant revenue, faces a long and risky development process. Nvidia's investment provides vital capital and a strategic partnership, helping to reduce financial and operational risks for Generate while positioning Nvidia at the forefront of AI-driven drug discovery.